Novo Nordisk and Eli Lilly manufacturing bottlenecks constrain the GLP-1 market

How the GLP-1 duopoly alters downstream consumption and healthcare funding structures

GLP-1 receptor agonists have altered the economics of metabolic health. A pharmaceutical duopoly now dictates global healthcare spending, consumer behavior, and segments of the food and beverage industry. Novo Nordisk and Eli Lilly control the vast majority of market share, value capture, and intellectual property for incretin-based therapies. Novo Nordisk generated over $29 billion in combined semaglutide revenues, and Eli Lilly experienced a 45% revenue surge driven by its dual-agonist portfolio. The rapid adoption of drugs like Wegovy and Zepbound diverts billions of dollars away from traditional chronic disease management and alters downstream consumption patterns.

An absolute duopoly constrained by extreme manufacturing bottlenecks drives this market. Upstream complexities in peptide synthesis and sterile fill-finish capacity create a physical ceiling on scale. Producing the active pharmaceutical ingredients for GLP-1 therapies requires specialized infrastructure, leaving Novo Nordisk and Eli Lilly in control of global supply. Their capital allocation decisions dictate the pace of supply chain expansion, forcing potential competitors into niche indications or delayed timelines. This structural bottleneck means supply defines the total addressable market over the next several years, yielding a prolonged period of pricing power and sustained volume growth for the incumbents.